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OBJECTIVES This study aimed to investigate the roles of intracoronary derived coronary flow velocity
reserve (CFVR) and myocardial perfusion scintigraphy (single photon emission computed
tomography, or SPECT) for management of an intermediate lesion in patients with
multivessel coronary artery disease.
BACKGROUND Evaluation of the functional significance of intermediate coronary narrowings (40% to 70%
diameter stenosis) is important for clinical decision making and risk stratification.
METHODS In a prospective, multicenter study, SPECT was performed in 191 patients with stable angina
and multivessel disease and scheduled for angioplasty (percutaneous transluminal coronary
angioplasty, or PTCA) of a severe coronary narrowing. Coronary flow velocity reserve was
determined selectively distal to an intermediate lesion in another artery using a Doppler guidewire.
Percutaneous transluminal coronary angioplasty of the intermediate lesion was deferred when
SPECT was negative or CFVR 2.0. Patients were followed for one year to document major
cardiac events (death, infarction, revascularization), related to the intermediate lesion.
RESULTS Reversible perfusion defects were documented in the area of the intermediate lesion in 30
(16%) patients; CFVR was positive in 46 (24%) patients. Percutaneous transluminal coronary
angioplasty of the intermediate lesion was deferred in 182 patients. During follow-up, 19
events occurred (3 myocardial infarctions, 16 revascularizations). Coronary flow velocity
reserve was a more accurate predictor of cardiac events than was SPECT; relative risk: CFVR
3.9 (1.7 to 9.1), p  0.05; SPECT 0.5 (0.1 to 3.2), p  NS. Multivariate analysis revealed
CFVR as the only significant predictor for cardiac events.
CONCLUSIONS Deferral of PTCA of intermediate lesions in multivessel disease is safe when CFVR 2.0
(event rate 6%). This selective evaluation of coronary lesion severity during cardiac
catheterization allows a more accurate risk stratification than does SPECT, which is
important for clinical decision making in this patient cohort. (J Am Coll Cardiol 2002;39:
852–8) © 2002 by the American College of Cardiology Foundation
During the last decade, there has been an enormous growth
in the number of percutaneous transluminal coronary an-
gioplasty (PTCA) procedures performed. According to
large registries, PTCA is increasingly performed for mul-
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tivessel coronary artery disease (50% to 70%), including
intermediate lesions in approximately 30% of the procedures
(1,2). Adequate patient selection for PTCA is of utmost
importance in view of the potential procedural complica-
tions and the incidence of restenosis (1,2). Angiographic
estimates using quantitative coronary angiography have
been shown to be poor predictors of its functional signifi-
cance (3–5). The recommended diagnostic approach in
multivessel coronary artery disease involves noninvasive
cardiac stress imaging modalities (i.e., echocardiography
and myocardial perfusion scintigraphy) to identify the func-
tional significance of coronary lesions (6–11), although
these techniques are limited in their ability to allocate wall
motion or perfusion defects to the “culprit” lesion.
Recently, intracoronary-derived hemodynamic parame-
ters using sensor-tipped angioplasty guidewires have been
introduced as an alternative strategy, allowing selective
assessment of functional severity of coronary narrowings
(12). Previous validation studies showed good agreement
(80% to 90%) between these parameters and the results of
noninvasive stress tests (13,14). Intracoronary hemody-
namic techniques facilitate decision making during diagnos-
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tic cardiac catheterization, allowing performance of ad hoc
angioplasty within the same session.
To date, a direct comparison between the noninvasive
and invasive tests for clinical decision making regarding
intermediate coronary lesions in patients with multivessel
coronary artery disease has not been performed. Therefore,
the purpose of the study was to compare the value of
intracoronary derived coronary flow velocity reserve
(CFVR) with myocardial perfusion scintigraphy in the
context of clinical decision making in these patients: the
Intermediate Lesions: Intracoronary Flow Assessment Ver-
sus 99mTc-MIBI SPECT (ILIAS) study.
METHODS
Patient selection. Patients with stable or unstable angina
(class 1 to 3 according to the Canadian Cardiovascular
Society; CCS or Braunwald’s classification I or II) were
screened between April 1997 and October 1999 for study
participation in six cardiac intervention centers in the
Netherlands. Coronary narrowing severity was determined
by visual assessment by a “heart team.” The team consisted
of an interventional cardiologist and a cardiac surgeon.
Patients with multivessel coronary artery disease, showing
one intermediate (defined as 40% to 70% diameter narrow-
ing) and at least one severe coronary narrowing (70%
diameter narrowing) in another artery at diagnostic cardiac
catheterization, were selected. Patients were eligible to
participate in the study if the severe lesion was accepted for
PTCA and if, from a clinical point of view, no definite
strategy was formulated for the intermediate lesion. Exclu-
sion criteria were as follows: patients with unstable angina
(according to Braunwald’s classification III), factors pre-
cluding dipyridamole infusion and/or assessment of intra-
coronary flow velocity, factors influencing coronary hemo-
dynamic parameters (e.g., left ventricular hypertrophy,
insulin dependent diabetes, previous myocardial infarction
in the area of interest, previous PTCA or coronary bypass
grafting of the segment of interest, significant left main
coronary artery stenosis). The protocol was approved by the
Institutional Review Boards of the participating institutions;
all patients gave written informed consent.
Study design. Patients were screened when the results of
the diagnostic cardiac catheterization were reviewed by the
heart team; inclusion and exclusion were verified. All
patients underwent single photon emission computed to-
mography (SPECT) imaging for noninvasive assessment of
functional severity of the intermediate lesion. A SPECT
was defined negative if no reversible perfusion defect was
determined in the area of the intermediate lesion. For the
purpose of this study, a negative SPECT includes normal
perfusion, reversible perfusion defects not allocated to the
area of interest and persistent defects.
Percutaneous transluminal coronary angioplasty of the
severe lesion was scheduled within one week after SPECT.
Coronary angiography was performed using the percutane-
ous femoral approach. During this procedure, CFVR mea-
surements were performed distal to the intermediate lesion
to determine its functional severity. A CFVR of 2.0 was
considered negative (12,15,16). Coronary lesion severity was
measured off line by quantitative coronary angiography
(QCA), using the CMS-QCA software version 3.32 (ME-
DIS, Leiden, Netherlands), as previously described (17).
The intermediate lesion was treated with PTCA if both
SPECT and CFVR were positive. Otherwise, the interme-
diate lesion was left untreated. The cardiac catheterization
procedure was completed by performing PTCA of the
severe lesion.
Clinical follow-up was performed at 3, 6 and 12 months.
In the event of persistent or recurrent anginal complaints,
SPECT imaging was repeated. CFVR was measured again
when repeat coronary angiography was performed. The
protocol warranted a (repeat) PTCA of the intermediate
lesion or coronary artery bypass grafting during follow-up if
angina was related to the intermediate lesion as determined
by a positive SPECT or a positive CFVR (i.e., CFVR 2.0).
Single photon emission computed tomography (SPECT).
Single photon emission computed tomography was per-
formed using 99mtechnetium-sestamibi, according to a two-
day stress/rest standard protocol, as previously described
(18). Dipyridamole (0.56 mg/kg intravenously during
4 min) was used as a hyperemic agent. Data acquisition and
reconstruction were performed according to the procedure
guideline for myocardial perfusion imaging of the Society of
Nuclear Medicine (19). Briefly, SPECT acquisition was
performed with a three-headed gamma camera equipped
with low-energy, high-resolution collimators. Images were
reconstructed using filtered back projection; no attenuation
correction was used.
An expert panel of nuclear medicine physicians, blinded
to the angiographic data, evaluated the scintigraphic images.
Perfusion defect severity was classified as dubious, mild,
moderate or severe. Improvement at rest of more than one
grade was considered to be a reversible perfusion defect.
Improvement of just one grade or no improvement was
considered to be a persistent perfusion defect. The result
was considered positive when a reversible defect was allo-
cated to the perfusion territory of the coronary artery of
Abbreviations and Acronyms
CFVR  coronary flow velocity reserve
ILIAS  Intermediate Lesions: Intracoronary Flow
Assessment Versus 99mTc-MIBI SPECT
study
LAD  left anterior descending coronary artery
LCx  left circumflex coronary artery
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiography
RCA  right coronary artery
SPECT  single photon emission computed tomography
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interest. Defects located in the anterior wall and septal
region were allocated to the left anterior descending artery
(LAD), defects in the lateral wall to the left circumflex
coronary artery (LCx) and inferior defects to the right
coronary artery (RCA). Apical defects were considered to be
located in the LAD region unless the defect extended to the
lateral (LCx) or inferior (RCA) wall. In the watershed
regions, the extension of a defect to either anterior wall
(LAD), lateral wall (LCx) or inferior wall (RCA) was
decisive for allocation to the vascular bed of a coronary
artery.
Coronary flow velocity reserve (CFVR) measurements.
Flow velocity was measured with a 0.014-inch Doppler
guidewire (FloWire, Endosonics, Rancho Cordova, Cali-
fornia). This wire was advanced distal to the coronary
narrowing. Distal flow velocity data at baseline and during
hyperemia (induced by an intracoronary bolus of adenosine,
15 g in the right coronary artery and 20 g in the left
coronary artery) were obtained; Doppler signals were pro-
cessed by real-time spectral analysis (20). The operator was
not aware of the results of the SPECT at the time of the
intracoronary measurements. Coronary flow velocity reserve
was computed as the ratio of hyperemic/basal average peak
blood flow velocity (21). Coronary flow velocity reserve
values were prospectively categorized according to the pre-
vious established cut-off value of 2.0 (12,15,16).
Outcome events. The primary outcome was defined as the
occurrence of one of the following events, related to the
intermediate lesion, during one year of follow-up: cardiac
death, myocardial infarction (defined as a total creatine
kinase concentration of more than twice the upper limit
and/or documented ST elevation or new Q-waves in at least
two electrocardiographic leads), or (repeat) PTCA of the
intermediate lesion or coronary artery bypass grafting. An
independent Critical Event Committee assigned the events
to the intermediate or the severe lesion, using all available
clinical and angiographical data but blinded to the initial
results of CFVR and SPECT. Moreover, they indicated if
these events were ischemia driven (i.e., objective evidence
that is predictive for a coronary narrowing causing myocar-
dial ischemia).
Data analysis. Patients were included in the final analysis if
results of both SPECT and CFVR were available for the
intermediate lesion. Based on these results, four groups were
identified: (A) both SPECT and CFVR negative, (B)
SPECT negative, CFVR positive, (C) SPECT positive and
CFVR negative and (D) both SPECT and CFVR positive.
Primary outcome event rates for the dichotomized results of
SPECT and CFVR were calculated separately for those
patients in whom a PTCA was deferred based on the
protocol (groups A, B and C), including relative risks and
95% confidence intervals (CI).
Univariate analysis was performed on relevant clinical,
angiographic and scintigraphic data for prediction of pri-
mary outcome events. Multivariate backward stepwise lo-
gistic regression analysis was performed for the prediction of
the primary outcome event (model 1), using those param-
eters that revealed a p  0.1 with univariate analysis.
Continuous variables were dichotomized on their median.
Subsequently, the dichotomized results of CFVR (model 2)
were added to model 1, and the predictive value of these two
models were compared using the chi-square statistic.
RESULTS
A total of 201 patients gave informed consent; 10 patients
were excluded from analysis because results of SPECT or
CFVR were not available for various reasons. Thus, 191
patients were evaluated according to the study protocol
(Table 1). The intermediate lesion was located in the RCA
in 20%, LAD in 47%, and LCx in 33%. The mean
percentage diameter stenosis on QCA was 54% (range 34%
to 74%) for the intermediate lesions and 79% (range 50% to
99%) for the severe lesions.
Single photon emission computed tomography showed
one or more reversible perfusion defects in 157 patients
(82%) and persistent defects in 67 patients (35%). More
specifically, in 30 patients (16%), a reversible perfusion
defect was allocated to the region of the intermediate lesion
by the panel of nuclear medicine physicians; no persistent
perfusion defects were present in these regions. A reversible
defect was allocated to the initial severe lesion in 153 (80%)
of the patients.
In total, 46 patients (24%) had a CFVR  2.0 in the
coronary artery with the intermediate lesion. In total, 124
patients entered group A, 37 group B, 21 group C and 9
group D. Thus, discordant results between SPECT and
CFVR concerning the intermediate lesion were observed in
58 (groups B and C) of the 191 patients (30% disagreement;
kappa 0.058, p 0.41). A PTCA of the intermediate lesion
was performed in 9 (group D) and deferred in 182 (groups
A, B and C) patients, according to the study protocol.
Table 1. Baseline Characteristics of the 191 Patients, Available
for Analysis
Patients
Male 71%
Age in years (mean, range) 61 (32–80)
History
Peripheral vascular disease 9 (5%)
Previous myocardial infarction 74 (39%)
Previous PTCA 22 (12%)
Previous CABG 0
Risk factors
Smoking 144 (75%)
Hypertension 74 (39%)
Hypercholesterolemia 113 (59%)
Non-insulin dependent diabetes mellitus 16 (8%)
Positive cardiac family history 106 (56%)
Anginal complaints
CCS class 1 18 (9%)
CCS class 2 65 (34%)
CCS class 3 95 (50%)
Braunwald I or II 13 (7%)
CABG  coronary artery bypass grafting; CCS  Canadian Cardiovascular Society;
PTCA  percutaneous transluminal coronary angioplasty.
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Outcome events. No follow-up was available for two
patients (both group A). These patients were excluded from
further analysis. During the one year of follow-up, 59
cardiac events occurred. Cardiac deaths did not occur. The
Critical Event Committee assigned 19 of these 59 events to
the intermediate lesion (primary outcome): 3 myocardial
infarctions, 3 coronary artery bypass grafting and 13 PTCA
procedures. In total, 8 (6%) events occurred in group A, 9
(24%) in group B, 1 (5%) in group C, and 1 (11%) in group
D. The Critical Event Committee considered objective
evidence that is predictive for a coronary narrowing causing
myocardial ischemia present in 13 of the 16 revasculariza-
tions (81%) (Table 2). There was uncertainty regarding this
evidence in two patients; it was absent in one patient.
Primary outcome event rates for patients with positive
and negative test results of SPECT versus positive and
negative test results of CFVR were determined separately
for the 180 patients of group A, B and C (Table 3). The
relative risk for the primary outcome event of a positive
CFVR was 3.9 (95% CI: 1.7 to 9.1; p  0.05). In contrast,
the relative risk of a positive SPECT was 0.5 (95% CI: 0.1
to 3.2; p  NS). These relative risks were statistically
significantly different (p  0.05).
Univariate analysis showed that gender, age, percentage
diameter stenosis on QCA, positive family history for
cardiac disease and CFVR (cut-off value 2.0) were signifi-
cant predictors (p  0.1) of primary outcome events. For
other geometric parameters measured with QCA (percent-
age area stenosis, minimal lumen diameter and reference
Table 3. Primary Outcome Events Related to the Intermediate
Lesion Presented for the Dichotomized Results of CFVR and
SPECT for Patients in Whom a PTCA Was Deferred and
Follow-Up Was Available (Groups A, B and C; n  180)
n Events (%) 95% CI
CFVR
Negative (CFVR 2.0) 143 9 (6.3%) 3.1–12.0
Positive (CFVR 2.0) 37 9 (24.3%) 12.4–41.6
RR 3.9* 1.7–9.1
SPECT
Negative (no reversible
perfusion defect in AOI)
159 17 (10.7%) 6.5–16.8
Positive (reversible
perfusion defect in AOI)
21 1 (4.8%) 0.3–25.9
RR 0.5* 0.1–3.2
*p  0.05 between both RRs.
AOI  area of interest; CFVR  coronary flow velocity reserve; CI  confidence
interval; RR  relative risk; SPECT  single photon emission computed tomography.
Table 2. Overview of Patients With Events Related to the Intermediate Lesion During One Year Follow-Up
Initial Follow-Up
Artery
With IM SPECT CFVR Event
Days to
Event SPECT CFVR
Ischemia
Driven Remarks
1 LAD   PTCA 10 NA  Yes
2 LCx   PTCA 37   Yes
3 LAD   PTCA 74 NA NA Yes UAP; Echo: wall motion abnormalities apex and
septum; CAG: no significant lesions in RCA
and LCx.
4 LCx   PTCA 98   Yes
5 RCA   PTCA 119   Yes
6 LAD   PTCA 137   Yes
7 LAD   PTCA 170   Yes
8 LAD   PTCA 179   Yes
9 LAD   PTCA 198 NA NA Yes Patient refused SPECT; X-ECG was positive
(ST depression in leads V3-V5)
10 LAD   PTCA 240 NA  ? PTCA performed following period of UAP with
ST depression in leads V1-V4
11 LCx   PTCA 270   Yes
12 LAD   PTCA 324 NA NA No PTCA performed based on clinical and
angiographic data only (in another hospital)
13 RCA   PTCA 365   Yes
14 LCx   CABG 155   Yes UAP; CAG: no significant lesions in LAD and
RCA; CABG after failure of PTCA LCx
(mainstem dissection)
15 LAD   CABG 190 NA NA ? X-ECG was positive, without specification
16 LAD   CABG 207   Yes
17 RCA   MI 156 NA NA Yes Inferior MI (Q), objectified by ECG changes
18 LAD   MI 268 NA NA Yes Anterior MI (Q), objectified by ECG changes
CAG: PTCA LAD
19 RCA   MI 297 NA NA Yes Inferior MI (non–Q), objectified by ECG
changes
CAG: thrombus in RCA
Of the 16 events associated with revascularization, at least 13 (81%) were ischemia driven, as determined by the Critical Event Committee.
  positive;   negative; CABG  diagnostic coronary angiography; CFVR  coronary flow velocity reserve; IM  intermediate lesion; LAD  left anterior descending
coronary artery; LCx  left circumflex coronary artery; MI  myocardial infarction; NA  not available; PTCA  percutaneous transluminal coronary angioplasty; RCA 
right coronary artery; SPECT  single photon emission computed tomography; UAP  unstable angina.
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diameter), no significant predictive value was detected using
univariate analysis. The multivariate models are depicted in
Table 4. Coronary flow velocity reserve was the only
significant predictor in model 2. Model 2 constituted a
statistically significant improvement over model 1 (1
2 
5.89; p  0.013).
DISCUSSION
The present study shows that intracoronary measurement of
a Doppler flow velocity parameter (CFVR) is useful for
management of an intermediate lesion in multivessel coro-
nary artery disease. Deferral of PTCA based on a cut-off
value of CFVR 2.0 is safe, as demonstrated by a lower
event rate (6%), in contrast to a high event rate in case of a
CFVR 2.0 (24%; relative risk 3.9); the prognostic value
was more accurate for CFVR than it was for SPECT
(relative risk 0.5). Measurement of CFVR allows selective
evaluation of functional severity of intermediate coronary
lesions, which facilitates risk stratification and may help
avoid unnecessary coronary interventions.
CFVR versus SPECT for clinical decision making. The
protocol was designed to compare a standard test (SPECT)
with an intracoronary diagnostic technique (CFVR).
Within one week, all patients underwent both tests, con-
forming to the recommendations for study designs for a
comparison of two diagnostic tests (22). Patients were
already scheduled for a PTCA procedure of a severe lesion;
CFVR of the intermediate lesion was measured during the
same session.
Extent and severity of perfusion abnormalities on
SPECT are the markers for cardiovascular risk (23,24). As
expected, severe myocardial perfusion defects were mainly
located in the region of the severe lesion, all treated with
PTCA. However, this study protocol was designed to
separately assess the functional status of multiple stenoses.
This required an allocation of the perfusion defects to the
severe and intermediate lesion and was scored as positive or
negative, which was necessary for the clinical decision to
perform or defer PTCA of that particular lesion.
The incidence of cardiac events related to the intermedi-
ate lesion was relatively low (19/191, 9.9%). Nevertheless,
CFVR had a better predictive value than did SPECT for
the occurrence of primary outcome events, predominantly
associated with coronary revascularizations, after an expec-
tative strategy (groups A, B and C) for the intermediate
lesion (relative risk 3.9 for CFVR 3.9, 0.5 for SPECT; p 
0.05, Table 3). These results suggest that SPECT is less
adequate than CFVR for clinical decision making in these
patients with multivessel disease, with respect to interme-
diate coronary lesions. The value of CFVR is also reflected
by the results of the multivariate logistic model, showing
that CFVR 2.0 is the only statistically significant predic-
tor of cardiac events during one year of follow-up (Table 4).
These findings may be explained by the ability of CFVR
to help evaluate coronary narrowings selectively, in contrast
to SPECT with its inherent limitation to allocate perfusion
defects to the culprit lesion in multivessel disease. This may
account for the lower concordance (70%) between SPECT
and CFVR than reported in previous validation studies,
predominantly concerning single vessel disease (80% to
90%) (13,15,16). Moreover, the pressure drop across the
intermediate lesion may induce a reduction of flow to
collateral dependent vascular territories in a minority of
patients, resulting in a larger reversible perfusion defect of
the vascular territory of the severe lesion rather than in a
separate reversible defect in the area of the intermediate
lesion (25).
Deferral of PTCA. The aim of risk stratification is to
identify patients with a high likelihood of future major
cardiac events who may benefit from invasive treatment.
The present study showed that deferral of PTCA is safe in
patients with CFVR 2.0; they had a relatively low event
rate of 6% (groups A and C). This contrasts with a 24%
event rate, predominantly determined by the need for
revascularization, in case of a positive CFVR. Against this,
if deferral would have been based solely on negative SPECT
(i.e., no reversible perfusion defect in the area of the
intermediate lesion), these patients would have experienced
a cardiac event rate of 11% (groups A and B), which is
higher than would be expected.
For noninvasive stress testing, low event rates (death and
nonfatal myocardial infarction) have been described for
patients with coronary artery disease, with and without
reversible perfusion defects determined by SPECT (4% to
Table 4. Results of 2 Multivariate Logistic Regression Models for Prediction of Primary
Outcome Events, Using the 180 Patients (Groups A, B and C) in Whom a PTCA of the
Intermediate Lesion was Deferred and Follow-Up Was Available
Model 1 (Chi-Square  8.412) Model 2* (Chi-Square  14.304)
Parameter OR 95% CI p OR 95% CI p
Gender (male) 0.41 0.15–1.15 0.09 0.50 0.17–1.44 0.20
Family history 2.51 0.76–8.35 0.13 2.30 0.67–7.83 0.18
% DS 55 on QCA 2.13 0.77–5.88 0.14 2.18 0.77–6.20 0.14
CFVR 2.0 — — — 3.74† 1.31–10.70 0.013
Model 1 is based on clinical, angiographic and scintigraphic data; in Model 2, the value of CFVR is added to model 1.
*Model 2 (including CFVR) versus Model 1: p  0.013 (see text). †p  0.05
CFVR coronary flow velocity reserve; CI confidence interval; DS diameter stenosis; OR odds ratio (for the presence
of the parameter); QCA  quantitative coronary angoigraphy.
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27% and 0% to 5%, respectively) (23,24,26–28). However,
the composite endpoint in the present study included
clinical and/or ischemia-driven revascularization proce-
dures, next to death and nonfatal myocardial infarction. For
invasive diagnostic strategies, safe deferral of PTCA with
low event rates (5% to 10%) has also been reported using
Doppler flow parameters (29,30). These studies did not
include a comparison with standard noninvasive diagnostic
techniques for clinical decision making.
Study limitations. The incidence of reversible perfusion
defects in the area of the intermediate lesion (16%) and a
CFVR 2.0 of this lesion (24%) was relatively low, indi-
cating that patients’ complaints were predominantly deter-
mined by the severe coronary narrowing. Consequently, the
absolute number of cardiac events related to the intermedi-
ate lesion during follow-up was low. Nevertheless, these
data showed that a clinically important risk stratification is
possible using CFVR with respect to cardiac events in those
patients in whom a PTCA was deferred.
Scintigraphic and flow velocity data analysis was per-
formed at the participating centers, instead of at indepen-
dent core laboratories. Nevertheless, this approach reflects
daily practice for clinical decision making in patients with
coronary artery disease.
Hyperemia was induced differently in this study for
SPECT (dipyridamole) and CFVR (adenosine). However,
diagnostic accuracies for adenosine were reported similar to
those of dipyridamole for SPECT (31).
It was anticipated that a high number of “hard” events
(i.e., myocardial infarction, death) related to the intermedi-
ate lesion would not occur during a relatively short
follow-up period of 12 months. The “hard” event rate was
1.6%. Therefore, the endpoint consisted predominantly of
revascularization procedures (16/19, 84%). The indepen-
dent Critical Event Committee considered objective evi-
dence that is indicative for myocardial ischemia present in
13 of these 16 revascularizations (81%, Table 2) based on
the clinical and angiographic findings, the results of perfu-
sion scintigraphy and/or CFVR measurements. These re-
sults indicate that the need for revascularization was not
driven by hidden biases of patients and/or physicians.
The results of this study were obtained in a selected
cohort of patients with stable angina and multivessel disease
as diagnosed during a cardiac catheterization and, therefore,
cannot be extrapolated without any reserve to other patient
cohorts selected for elective coronary angioplasty.
Clinical implications. It is commonly accepted that diag-
nostic cardiac catheterization should be preceded by objec-
tive evidence that is predictive for a coronary narrowing
causing myocardial ischemia. This includes noninvasive
stress testing using perfusion scintigraphy in case of non-
conclusive electrocardiographic exercise testing. However,
the present study showed that the role of SPECT is limited
for clinical decision making about intermediate lesions in
the presence of multivessel coronary artery disease.
Deferral of PTCA of intermediate lesions in multivessel
disease is safe when CFVR is negative. Implementation of
CFVR measurements during cardiac catheterization facili-
tates subsequent PTCA if necessary, which avoids addi-
tional scintigraphic testing and repeat cardiac catheteriza-
tion, reducing patient discomfort and procedural costs.
Selective evaluation of coronary lesion severity during car-
diac catheterization using CFVR allows risk stratification; it
identifies patients who will have a significantly higher event
rate, predominantly associated with revascularizations, dur-
ing follow-up.
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